Compare STMicroelectronics NV (STM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs Vertex Pharmaceuticals Incorporated — how do they compare? STMicroelectronics NV trades at $65.31 (market cap $55.80B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× STMicroelectronics NV's market cap, and STMicroelectronics NV pays a 0.58% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| STM | VRTX | |
|---|---|---|
Market Cap | $55.80B | $121.95B |
Sector | Financials | Health |
52-Week High | $79.91 | $529.59 |
52-Week Low | $21.20 | $366.54 |
Enterprise Value | $54.01B | $116.69B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM stock trades at $65.43, up 5.43% in the past 24 hours, with a bearish technical signal and mixed earnings history. The company shows declining revenue and net income margins but maintains positive cash flow from operations. Recent news highlights AI partnerships and automotive chip demand as potential growth drivers.
Outlook remains cautious due to elevated P/E ratio of 386.13 and recent earnings misses, though analyst consensus is bullish with a $72.33 price target. Key risks include semiconductor cycle volatility and execution challenges in maintaining profitability amid revenue pressures.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
